Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Other Accumulated Expenses (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Other Accumulated Expenses data on record, last reported at $674391.0 in Q1 2025.

  • For Q1 2025, Other Accumulated Expenses rose 86.53% year-over-year to $674391.0; the TTM value through Mar 2025 reached $674391.0, up 86.53%, while the annual FY2025 figure was $674391.0, 86.53% up from the prior year.
  • Other Accumulated Expenses reached $674391.0 in Q1 2025 per SXTC's latest filing, up from $361543.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.2 million in Q1 2022 and bottomed at $361543.0 in Q1 2024.
  • Average Other Accumulated Expenses over 5 years is $761430.6, with a median of $789232.0 recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: soared 184.9% in 2021, then crashed 54.19% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $819677.0 in 2021, then surged by 41.8% to $1.2 million in 2022, then plummeted by 32.1% to $789232.0 in 2023, then plummeted by 54.19% to $361543.0 in 2024, then skyrocketed by 86.53% to $674391.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $674391.0 in Q1 2025, $361543.0 in Q1 2024, and $789232.0 in Q1 2023.